newsfilter
← Latest News
GlobeNewswire·

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

YDES
  • YD Bio Limited, EG BioMed, and digital health provider JoiiUp announced a strategic collaboration to integrate an AI Cancer Risk Assessment into JoiiUp's JoiiSports app.
  • The Assessment was jointly developed by YD Bio and EG BioMed with clinical validation using over 1,200 records from three Taipei Medical University affiliated hospitals.
  • The non-invasive tool analyzes ten cancer types using online questionnaires, AI models, demographic data, lifestyle habits, and family history without requiring blood draws or imaging.
  • JoiiUp brings over 12 years of workplace health promotion experience to support employee wellness programs for more than 400 companies.
  • Users can access the Assessment via Single Sign-On within the JoiiSports app to generate personalized risk reports and targeted lifestyle recommendations.
  • Initial deployment will focus on JoiiUp's corporate partner network before expanding to healthcare institutions for patient education and consultation.
  • Dr. Ethan Shen of YD Bio stated the tool is a step toward a comprehensive cancer management pathway spanning risk assessment, early detection, and precision medicine.
  • Dr. Ruo-Kai Lin of EG BioMed emphasized the goal of making clinically validated information more accessible to help users discuss risks with healthcare professionals.
  • The Assessment is a risk-stratification and health guidance tool that does not diagnose cancer, predict disease probability, or replace professional medical evaluation or recommended screening.
  • YD Bio is advancing a merger transaction with EG BioMed that was initiated via a Memorandum of Understanding in January 2026 and is anticipated to close in 2026.
  • The press release includes forward-looking statements regarding business plans, partnership integration, and future expansion that are subject to various risks and uncertainties.